" class="no-js "lang="en-US"> Accuray - Medtech Alert
Wednesday, September 27, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Accuray | Pharmtech Focus

Accuray

About Accuray

Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Related Story

Appointments

 Accuray Announces Suzanne Winter

Accuray Announces Suzanne Winter, President, Promoted to President and CEO; Joshua Levine Will Retire as CEO and Board Member

April 28 2022

Accuray Incorporated (NASDAQ: ARAY) announced today that Suzanne Winter, President, will succeed Joshua Levine as the company’s Chief Executive […]

Diseases

 Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients | Pharmtech Focus

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

October 25 2021

Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients […]

Diseases

 C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities | Pharmtech Focus

C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities

October 4 2021

C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed […]